CommercialCoverageMedium impact
Fluticasone HFA - added to all BCBSRI Commercial Formularies
Blue Cross Blue Shield of Rhode Island·RI · Pulmonology, Allergy & Immunology, Family Medicine +2 more·Physician / Facility
Effective date
Apr 1, 2024
We identified it
Jun 19, 2026
Summary
BCBS Rhode Island has added Fluticasone HFA to all commercial formularies as a preferred tier medication, effective retroactively to April 1, 2024. This provides an alternative inhaled corticosteroid option due to Flovent HFA discontinuation and Asmanex HFA supply shortages.
Action Required
Immediately: Update prescribing protocols and billing systems to reflect Fluticasone HFA as preferred tier for BCBS RI commercial plans. Providers should consider switching patients from discontinued Flovent HFA or supply-constrained Asmanex HFA to Fluticasone HFA when clinically appropriate. Update formulary references and prior authorization workflows accordingly.